Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
3 clusters · 9 sources · 24 days · First seen · Last updated
Windward Bio US IPO process
Overview
Basel-based biotechnology company Windward Bio AG initiated its United States initial public offering (IPO) process by filing to raise up to $365 million. The company intends to use the funds to accelerate the development of long-acting antibody treatments for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory skin diseases. Its lead candidate, WIN378, is designed to block thymic stromal lymphopoietin (TSLP) to reduce injection frequency for patients.
Following the filing, Windward Bio completed its Nasdaq debut by pricing the IPO at $17 per share. The company raised gross proceeds of approximately $251.2 million, which included the full exercise of underwriters’ options. This total consists of $175 million from public investors and a $50 million concurrent private placement with Sanofi Foreign Participations B.V.
These funds are earmarked for clinical trials of next-generation biologic drugs, specifically for lead candidates WIN378 and WIN027. WIN378 is currently being evaluated in Phase 2/3 asthma and Phase 2 COPD studies, aiming to provide dosing every six months. Following its market debut, the company reached a market capitalization of approximately $1.69 billion. Windward Bio utilizes a model of licensing clinical-stage assets from various Chinese biotechnology firms, including programs from Sichuan Kelun-Biotech Biopharmaceutical, Harbour BioMed, and Qyuns Therapeutics.
Entities
Basel · Nasdaq · Sanofi · Luca Santarelli · Windward Bio AG
Timeline
-
[BUSINESS] 3 sourcesWindward Bio raises $251.2 million in Nasdaq IPO
Basel-based Windward Bio raised $251.2 million through a Nasdaq IPO and a $50 million private placement from Sanofi to fund its ultra-long-acting antibody drug trials.
-
[BUSINESS] 7 sourcesWindward Bio raises $225 million in Nasdaq debut
Swiss biotech Windward Bio raised $225 million through a Nasdaq IPO and a private placement with Sanofi to fund development of long-acting biologic drugs for asthma and COPD.
-
[BUSINESS] 4 sourcesWindward Bio files for $365 million US IPO
Swiss biotech firm Windward Bio has filed for a US IPO, seeking up to $365 million to develop long-acting antibody treatments for asthma and inflammatory diseases.
Sources
bahrainbulletin.com · european-biotechnology.com · financial-news.co.uk · laotiantimes.com · medcitynews.com · ohsem.me · pulse2.com · tekedia.com · theqldr.com.au
This summary has been updated 1 time: see revision history